Submissions from 2022
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism., Maysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, Rui Luo, Weelic Chong, Daniel P Silver, Frederick Fellin, Rebecca Jaslow, AnaMaria Lopez, Terrence P Cescon, Wei Jiang, Ronald Myers, Qiang Wei, Bingshan Li, Massimo Cristofanilli, and Hushan Yang(Article)
Anticoagulation Safety, Akshay Amaraneni, Venu Chippa, and Andrew C. Rettew(Book)
Submissions from 2021
Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer., Yanin Chávarri-Guerra, Catherine A Marcum, Carolyn B Hendricks, Deborah Wilbur, Terrence P Cescon, Christopher Hake, Julio Abugattas, Yenni Rodriguez, Cynthia Villarreal-Garza, Kai Yang, Aleck Cervantes, Sharon Sand, Danielle Castillo, Joseph Herzog, Janet Mokhnatkin, Mina S Sedrak, and Enrique Soto-Perez-de-Celis(Article)
Submissions from 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408., Andrew M Evens, Fangxin Hong, Thomas M Habermann, Ranjana H Advani, Randy D Gascoyne, Thomas E Witzig, Andrew Quon, Erik A Ranheim, Stephen M Ansell, Puneet Singh Cheema, Philip A Dy, Timothy E O'Brien, Jane N Winter, Terrence P Cescon, Julie E Chang, and Brad S Kahl(Article)
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors., Chun Wang, Zhaomei Mu, Zhong Ye, Zhenchao Zhang, Maysa M Abu-Khalaf, Daniel P Silver, Juan P Palazzo, Geetha Jagannathan, Frederick M Fellin, Saveri Bhattacharya, Rebecca J Jaslow, Theodore N Tsangaris, Adam Berger, Manish Neupane, Terrence P Cescon, AnaMaria Lopez, and Kaelan Yao(Article)
Submissions from 2018
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203., Ann H Klopp, Anamaria R Yeung, Snehal Deshmukh, Karen M Gil, Lari Wenzel, Shannon N Westin, Kent Gifford, David K Gaffney, William Small, Spencer Thompson, Desiree E Doncals, Guilherme H C Cantuaria, Brian P Yaremko, Amy Chang, Vijayananda Kundapur, Dasarahally S Mohan, and Michael L Haas(Article)
Submissions from 2014
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer., Andre Konski, Joshua E Meyer, Michael Joiner, Michael J Hall, Philip Philip, Anthony Shields, Erin McSpadden, Minsig Choi, Beth Adaire, Gail Duncan, Neal J Meropol, Terrence P Cescon, and Steven J Cohen(Article)
Submissions from 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study., Jeffrey R Infante, Tony R Reid, Allen L Cohn, William J Edenfield, Terrence P Cescon, John T Hamm, Imtiaz A Malik, Thomas A Rado, Philip J McGee, Donald A Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim, and Thomas H Cartwright(Article)
Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)., Andra V Krauze, Minhee Won, Christian Graves, Ben W Corn, Thierry M Muanza, Steven P Howard, Arul Mahadevan, Christopher J Schultz, Michael L Haas, Minesh P Mehta, and Kevin A Camphausen(Article)
Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial., Susan V Montgomery, Andrea M Barsevick, Brian L Egleston, Ruth Bingler, Karen Ruth, Suzanne M Miller, John Malick, Terrence P Cescon, and Mary B Daly(Article)
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43., Kalliopi P Siziopikou, Stewart J Anderson, Melody A Cobleigh, Thomas B Julian, Douglas W Arthur, Ping Zheng, Eleftherios P Mamounas, Eduardo R Pajon, Robert J Behrens, Janice F Eakle, Nick C Leasure, James N Atkins, Jonathan A Polikoff, Thomas E Seay, Worta J McCaskill-Stevens, Rachel Rabinovitch, and Joseph P Costantino(Article)
Submissions from 2011
A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC), J Infante, A Cohn, T R. Reid, W Edenfield, Terrence P Cescon, J Hamm, J Tarazi, S Kim, B Rosbrook, and T Cartwright(Abstract)
Submissions from 2010
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial., John D Hainsworth, David R Spigel, Bobby L Clark, Dianna Shipley, Dana S Thompson, Cynthia Farley, Kimberly West-Osterfield, Cassie M Lane, Terrence P Cescon, Martin J Bury, and F Anthony Greco(Article)
Oxaliplatin plus capecitabine in combination with radiation therapy for treatment of cervical cancer: A phase II study, L Levine(Abstract)
Submissions from 2008
Intention to communicate BRCA1/BRCA2 genetic test results to the family., Andrea M Barsevick, Susan V Montgomery, Karen Ruth, Eric A Ross, Brian L Egleston, Ruth Bingler, John Malick, Suzanne M Miller, Terrence P Cescon, and Mary B Daly(Article)
Submissions from 2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer., Sheri K Dennison, Samuel A Jacobs, John W Wilson, Janell Seeger, Terrence P Cescon, Jane M Raymond, Charles E Geyer, Norman Wolmark, and Sandra M Swain(Article)
Prostate cancer risk assessment program: a 10-year update of cancer detection., Veda N Giri, Jennifer Beebe-Dimmer, Mark Buyyounouski, Andre Konski, Steven J Feigenberg, Robert G Uzzo, Gerald Hanks, Andrew K Godwin, David Y T Chen, Robert Gordon, Terrence P Cescon, Susan Raysor, and Deborah Watkins-Bruner(Article)
Submissions from 2005
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program., James N Atkins, Samuel A Jacobs, H Samuel Wieand, Roy E Smith, William J John, Linda H Colangelo, Victor G Vogel, J Philip Kuebler, Terrence P Cescon, Barbara J Miller, Charles E Geyer, and Norman Wolmark(Article)
Submissions from 2001
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck., M Suntharalingam, Michael L Haas, D A Van Echo, R Haddad, M C Jacobs, S Levy, W C Gray, R A Ord, and B A Conley(Article)
Submissions from 2000
Expression analysis of human HL60 cells exposed to 60 Hz square- or sine-wave magnetic fields., E K Balcer-Kubiczek, G H Harrison, C C Davis, Michael L Haas, and B H Koffman(Article)
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck., M Suntharalingam, Michael Haas, B A Conley, M J Egorin, S Levy, S Sivasailam, J M Herman, M C Jacobs, W C Gray, R A Ord, J A Aisner, and D A Van Echo(Article)
The use of concurrent chemotherapy with high-dose radiation before surgical resection in patients presenting with apical sulcus tumors., M Suntharalingam, J R Sonett, Michael L Haas, L A Doyle, P F Hausner, J Schuetz, and M J Krasna(Article)
Submissions from 1999
Utility of radiation in the prevention of heterotopic ossification following repair of traumatic acetabular fracture., Michael L Haas, A S Kennedy, C C Copeland, J W Ames, M Scarboro, and R G Slawson(Article)